AstraZeneca discontinued its lead T-cell receptor therapy NT-125 and two armored CAR-T candidates, AZD5851 and AZD6422, citing strategic portfolio prioritization. Despite acquiring Neogene Therapeutics for its TCR platform, the company refocused its cell therapy efforts, halting a phase 1 trial involving patients with various solid tumors. This retreat highlights shifting priorities within AstraZeneca's broad oncology R&D pipeline, favoring platform potential over individual assets.